BioNTech updates data showing nearly doubled median OS
BioNTech says updated data show Gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.